📊 BGLC Key Takeaways
Investment Thesis
BioNexus Gene Lab Corp is a pre-revenue profitability stage company with severe operational challenges. Despite having modest revenue of $6.9M, the company is burning cash at an alarming rate (-$2.8M operating cash flow) with negative margins across all profitability measures (-28.1% net margin, -27.8% operating margin). The combination of persistent unprofitability, significant cash burn relative to asset base, and zero insider confidence signals acute fundamental distress.
BGLC Strengths
- Strong liquidity position with 8.30x current ratio and $1.2M in cash reserves
- Minimal debt burden with 0.00x debt-to-equity ratio reducing financial distress risk
- Relatively low absolute liabilities at $805K provide some buffer
BGLC Risks
- Severe cash burn of $2.8M in operating activities against only $1.2M cash on hand creates acute solvency risk within 5-6 months
- Negative gross margin of 15.7% indicates fundamental business model problems with cost structure unsustainable at current revenue levels
- Consistently negative profitability across all metrics (ROA -25.6%, ROE -28.6%, net margin -28.1%) with zero evidence of operational improvement trajectory
- Negative free cash flow of -$2.8M and -40.8% FCF margin demonstrates the company is not operationally viable at present scale
- Zero insider Form 4 filings in last 90 days suggests complete lack of insider confidence or activity
Key Metrics to Watch
- Operating cash flow trajectory and monthly burn rate relative to cash reserves
- Gross margin improvement - critical indicator of cost structure viability
- Revenue growth rate and path to operating break-even
- Insider trading activity and capital raise announcements
BGLC Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 8.30x current ratio provides a solid financial cushion.
BGLC Profitability Ratios
BGLC vs Healthcare Sector
How BioNexus Gene Lab Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BGLC Balance Sheet & Liquidity
BGLC 5-Year Financial Trend
5-Year Trend Summary: BioNexus Gene Lab Corp's revenue has declined by 14% over the 5-year period, indicating business contraction. The most recent EPS of $-0.17 indicates the company is currently unprofitable.
BGLC Growth Metrics (YoY)
BGLC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.5M | -$709.0K | $-0.40 |
| Q2 2025 | $2.0M | $95.3K | $0.05 |
| Q1 2025 | $2.1M | -$103.8K | $-0.01 |
| Q3 2024 | $2.6M | -$69.1K | N/A |
| Q2 2024 | $2.0M | -$69.1K | N/A |
| Q1 2024 | $2.4M | -$69.1K | N/A |
| Q2 2023 | $2.5M | $17.1K | N/A |
| Q1 2023 | $2.4M | $17.1K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BGLC Capital Allocation
BGLC SEC Filings
Access official SEC EDGAR filings for BioNexus Gene Lab Corp (CIK: 0001737523)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BGLC
What is the AI rating for BGLC?
BioNexus Gene Lab Corp (BGLC) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BGLC's key strengths?
Strong liquidity position with 8.30x current ratio and $1.2M in cash reserves. Minimal debt burden with 0.00x debt-to-equity ratio reducing financial distress risk.
What are the risks of investing in BGLC?
Severe cash burn of $2.8M in operating activities against only $1.2M cash on hand creates acute solvency risk within 5-6 months. Negative gross margin of 15.7% indicates fundamental business model problems with cost structure unsustainable at current revenue levels.
What is BGLC's revenue and growth?
BioNexus Gene Lab Corp reported revenue of $6.9M.
Does BGLC pay dividends?
BioNexus Gene Lab Corp does not currently pay dividends.
Where can I find BGLC SEC filings?
Official SEC filings for BioNexus Gene Lab Corp (CIK: 0001737523) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BGLC's EPS?
BioNexus Gene Lab Corp has a diluted EPS of $-1.09.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.